* Mesa Laboratories Inc MLAB.OQ MLAB.O is expected
to show a
rise in quarterly revenue when it reports results on February 1
(estimated).
* The Lakewood Colorado-based company is expected to report
a
5.6% increase in revenue to $57.74 million from $54.7 million a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Mesa Laboratories
Inc is
for earnings of 14 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Mesa
Laboratories
Inc is $205, above its last closing price of $193.27.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.31 -0.31 0.24 Beat 177.4
Jun. 30 2022 0.91 1.00 -0.27 Missed -127.1
Mar. 31 2022 0.48 0.48 -0.34 Missed -170.8
Dec. 31 2021 0.42 0.42 0.61 Beat 45.2
Sep. 0.50 0.42 0.70 Beat 66.7
30 2021
Jun. 30 2021 0.11 0.10 0.38 Beat 280
Mar. 31 2021 0.18 0.26 0.74 Beat 190.2
Dec. 31 2020 0.32 0.33 -0.89 Missed -373.8
This summary was machine generated January 30 at 13:48 GMT. All
figures in US dollars unless otherwise stated